Problem

RTHM addresses the fragmented, uncertain care available to people with complex, infection-associated chronic illnesses such as Long COVID, ME/CFS, POTS, MCAS, and hEDS. These patients often have multi-system symptoms, incomplete explanations, disconnected medical records, and few clinicians equipped to interpret the condition. The access problem is acute: ME/CFS specialists and clinical centers are scarce, and many do not accept insurance or have waiting lists lasting years. Long COVID also creates substantial economic pain; a 2025 review estimated roughly $170 billion in annual lost US earnings, with 2–4 million working-age Americans unemployed or out of the labor force because of the illness.

The killer use case is a patient whose persistent fatigue, post-exertional symptoms, dysautonomia, pain, cognitive problems, or other post-viral symptoms have not been coherently diagnosed or managed. Instead of continuing a costly cycle of disconnected appointments and trial-and-error treatments, that patient needs one place to assemble the evidence, identify patterns, access appropriate testing, and determine which interventions are helping.

Product / Service

RTHM combines a free AI-enabled intelligence platform with a paid, virtual-first clinical service. Patients can integrate medical records and complete health assessments and validated questionnaires; RTHM then analyzes labs, encounter notes, medications, and symptom history to identify possible root causes and generate tailored next steps. The platform is intended to connect the dots across complex illness rather than function as ordinary primary care.

Patients who need more support can join RTHM Clinic, a telehealth concierge membership. The clinic provides medical-record review, access to more than 300 research-backed biomarkers, up to 12 clinician visits annually, panel case reviews, a dedicated care navigator and health advisor, and broader access to medications, diagnostics, and referrals. Patients track symptoms, wearable-derived vitals, and treatment changes so clinicians can iterate on the care plan. The clinic is priced at $1,080 per month plus a $1,500 onboarding fee, with a three-month minimum; the free platform supplies an entry point while the clinic monetizes intensive, longitudinal care.

Market

RTHM competes in digital health and AI-enabled telemedicine for complex chronic illness, with a focused position in Long COVID and related post-infectious conditions. Its alternatives include hospital-based Long COVID programs, a small number of ME/CFS and related-disease specialists, and broader virtual-care or functional-medicine providers. The hospital market is substantial—research found that 43 of the top 50 US hospitals offered Long COVID services—but those programs commonly rely on referrals and specialist coordination, while access remains geographically uneven. A market database names My Premise Health, BitCare, and TelevisitMD as competitors or comparables, although they appear to be broader telemedicine businesses rather than direct like-for-like specialists.

RTHM appears to have moved beyond a pre-revenue concept but remains an early-stage private company. It was founded in 2018, participated in Y Combinator’s Winter 2022 batch, and is listed by PitchBook as having 20 employees, $6.6 million raised, and a 2025 deal categorized as generating revenue. Its paid clinic and treatment offerings provide a clear monetization model, but the public evidence does not disclose current revenue, patient volume, or outcomes at scale, so traction is better characterized as funded commercial validation than demonstrated market scale.